- $2.87bn
- $11.07bn
- $6.40bn
- 78
- 92
- 31
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.9 | ||
| PEG Ratio (f) | 1.12 | ||
| EPS Growth (f) | 2.65% | ||
| Dividend Yield (f) | 10.57% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.08 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 4.88 | ||
| Price to Sales | 0.45 | ||
| EV to EBITDA | 6.79 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.77% | ||
| Return on Equity | 429.85% | ||
| Operating Margin | 12.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6,532 | 6,304 | 6,174 | 6,263 | 6,403 | 6,224.77 | 6,280.89 | -3.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -31.71 | -38.2 | -24.25 | -1.94 | -10.91 | +1.23 | +5.94 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 11th, 2021
- Public Since
- May 14th, 2021
- No. of Shareholders
- 64,928
- No. of Employees
- 10,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 257,950,149
- Address
- 30 Hudson Street, Fl 33, JERSEY CITY, 07302
- Web
- https://www.organon.com/
- Phone
- +1 5514306000
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for OGN
Q1 2025 Organon & Co Earnings Release
Organon & Co Annual Shareholders Meeting
Q2 2025 Organon & Co Earnings Release
Similar to OGN
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
What is the Organon & Co share price?
As of Today at 22:28 UTC, shares in Organon & Co are trading at $11.12. This share price information is delayed by 15 minutes.
How has the Organon & Co share price performed this year?
Shares in Organon & Co last closed at $11.12 and the price had moved by -37.77% over the past 365 days. In terms of relative price strength the Organon & Co share price has underperformed the S&P500 Index by -41.49% over the past year.
What are the analyst and broker recommendations for Organon & Co?
The overall consensus recommendation for Organon & Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Organon & Co dividend yield?
The Organon & Co dividend yield is 10.07% based on the trailing twelve month period.
Does Organon & Co pay a dividend?
Last year, Organon & Co paid a total dividend of $1.12, and it currently has a trailing dividend yield of 10.07%. We do not have any data on when Organon & Co is to next pay dividends.
When does Organon & Co next pay dividends?
We do not have data on when Organon & Co is to next pay dividends. The historic dividend yield on Organon & Co shares is currently 10.07%.
How do I buy Organon & Co shares?
To buy shares in Organon & Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Organon & Co?
As of the previous close price of $11.12, shares in Organon & Co had a market capitalisation of $2.87bn.
Where are Organon & Co shares listed?
Here are the trading details for Organon & Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: OGN
What kind of share is Organon & Co?
Based on an overall assessment of its quality, value and momentum Organon & Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Organon & Co share price forecast for 2025?
The analyst consensus target price for shares in Organon & Co is $20.40. That is 83.45% above the last closing price of $11.12.
Analysts covering Organon & Co currently have a consensus Earnings Per Share (EPS) forecast of $3.77 for the next financial year.
Find out moreWhat is the trend in the Organon & Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Organon & Co. Over the past six months, its share price has underperformed the S&P500 Index by -30.03%.
As of the last closing price of $11.12, shares in Organon & Co were trading -35.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Organon & Co PE Ratio?
The Organon & Co PE ratio based on its reported earnings over the past 12 months is 2.9. The shares last closed at $11.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Organon & Co?
We do not have data on Organon & Co's directors